Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (2023)
Attributed to:
Predicting disease flare and treatment response in inflammatory bowel disease
funded by
FLF
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2468-1253(22)00389-2
PubMed Identifier: 36481043
Publication URI: http://europepmc.org/abstract/MED/36481043
Type: Journal Article/Review
Volume: 8
Parent Publication: The lancet. Gastroenterology & hepatology
Issue: 2